HC Scientific Bags over ￥10M in Series A+ Funding Round

According to PEdaily.cn, Chengdu Hanchen Scientific Technology Co., Ltd. ("HC Scientific") has completed the Series A+ financing of tens of millions yuan, with participation from Northern Light Venture Capital, BioTrack Capital, InnoStar Venture (a venture arm of Fosun Group) and Ultima Capital. Proceeds of this round will be used for the development, market expansion and team building of automated molecular detection system.

In 2017, HC Scientific obtained millions of yuan in the angel round from Ultima Capital. In July 2018, it completed the Series A financing of tens of millions yuan from Fosun Group and BioTrack Capital.

Founded in 2016, HC Scientific is a high-tech company engaged in research and development, production and marketing of medical devices, focusing on automated molecular testing through independent research and development. HC Scientific is committed to meeting the demands of the Chinese and global customers in the clinical diagnosis, health genetic testing and molecular breeding of agriculture.

GeneMatrix independently developed by HC Scientific is a stand-out system with technology of high-throughput and automated molecular detection in China, which is able to replace the imported products. It has been widely used in modern agriculture, scientific research, health management and other fields in China, and has been widely recognized by customers. In addition, HC Scientific has a number of high-throughput molecular diagnostic systems under development.

Founded in 2005, Northern Light is a venture capital firm targeting early-stage opportunities of innovation and disruptive technology. It has 5 RMB funds and 5 USD funds with managed capital of 4.5 billion dollars.

Northern Light focuses on 3 main sectors including TMT, advanced technology (AI, internet of things, robotics, advanced manufacturing, etc.), and healthcare (medical devices, E-health, medical services, and biological, genomic and in-vitro therapeutics).

Founded in 2017, BioTrack Capital is a dedicated healthcare venture capital firm focused on building and incubating innovative life science companies in China. The company focuses on innovative biotech companies, innovative MedTech companies, and innovative business models in healthcare which are led by outstanding entrepreneurs.